Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Aug 13, 2022 11:41am
147 Views
Post# 34893959

RE:More than 55 million people Worldwide with dementia

RE:More than 55 million people Worldwide with dementia
GoldenInvestor wrote: Fitting stat just heard on the news  


GUD has two potential paths to AD at this time ...
1.  EXELON (now)
2.  future drug developments though existing/future partners 

--------

I am very much a believer that AD is being poorly tackled at this time - even with the global drugs in the funnel.

I think the future may include opportunities with either antivirals or autoimmune drugs.
More likely in a combination of the two ... with inflammation reduction as a key component.  Time will tell.

As R&D continues, there is a real potential to link the gut and the brain, excess iron to the brain via the gut ... and ... viral triggers (e.g. VZV virus/COVID/SARs/ causing latent herpes simplex 1 to activate in the brain and bring on the effects of AD.

Early days - but - I see GUD is sitting as pretty as one can in such partnerships.

I personally think you need to solve gut issues before you really put a dent in brain diseases.  

https://www.health.harvard.edu/diseases-and-conditions/the-gut-brain-connection#:~:text=The%20brain%20has%20a%20direct,send%20signals%20to%20the%20gut.
<< Previous
Bullboard Posts
Next >>